Table 4.
Serotype Distribution in All-Cause Community-Acquired Pneumonia and in Pneumococcal Community-Acquired Pneumonia According to Presence of Underlying Conditions by Age Group, 2016-2018
| Diabetes Mellitus | COPD | Previous Pneumonia | Tobacco Cigarrette Smokers | Chronic Heart Failure | Chronic Renal Failure | Asthma | No Underlying Diseases | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | |
| 18–64 y | ||||||||||||||||
| All-cause CAP (n = 401) | 46 | 11.5 | 39 | 9.7 | 66 | 16.4 | 141 | 35.2 | 13 | 3.2 | 6 | 1.5 | 48 | 12.0 | 95 | 23.7 |
| PCV13 serotypes | 6 | 13.0 | 5 | 12.8 | 7 | 10.6 | 14 | 9.9 | 2 | 15.4 | 0 | 0.0 | 6 | 12.5 | 11 | 11.6 |
| PCV15 serotypes | 7 | 15.2 | 6 | 15.4 | 7 | 10.6 | 15 | 10.6 | 2 | 15.4 | 0 | 0.0 | 7 | 14.6 | 12 | 12.6 |
| PCV20 serotypes | 12 | 26.1 | 11 | 28.2 | 13 | 19.7 | 37 | 26.2 | 3 | 23.1 | 2 | 33.3 | 15 | 31.3 | 25 | 26.3 |
| Most prevalent serotypes (≥1% in total cases) | ||||||||||||||||
| 1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| 14 | 0 | 0.0 | 1 | 2.6 | 0 | 0.0 | 3 | 2.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| 19A | 1 | 2.2 | 1 | 2.6 | 1 | 1.5 | 1 | 0.7 | 1 | 7.7 | 0 | 0.0 | 2 | 4.2 | 0 | 0.0 |
| 3 | 3 | 6.5 | 3 | 7.7 | 6 | 9.1 | 7 | 5.0 | 1 | 7.7 | 0 | 0.0 | 4 | 8.3 | 7 | 7.4 |
| 7F | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 3 | 3.2 |
| 8 | 4 | 8.7 | 3 | 7.7 | 5 | 7.6 | 20 | 14.2 | 1 | 7.7 | 2 | 33.3 | 7 | 14.6 | 11 | 11.6 |
| 12F | 1 | 2.2 | 2 | 5.1 | 0 | 0.0 | 1 | 0.7 | 0 | 0.0 | 0 | 0.0 | 1 | 2.1 | 1 | 1.1 |
| CAP due to Streptococcus pneumoniae (n = 141; 35.2%) | 15 | 10.6 | 18 | 12.8 | 19 | 13.5 | 47 | 33.3 | 5 | 3.5 | 2 | 1.4 | 18 | 12.8 | 31 | 22 |
| PCV13 serotypes | 6 | 40.0 | 5 | 27.8 | 7 | 36.8 | 14 | 29.8 | 2 | 40.0 | 0 | 0.0 | 6 | 33.3 | 11 | 35.5 |
| PCV15 serotypes | 7 | 46.7 | 6 | 33.3 | 7 | 36.8 | 15 | 31.9 | 2 | 40.0 | 0 | 0.0 | 7 | 38.9 | 12 | 38.7 |
| PCV20 serotypes | 12 | 80.0 | 11 | 61.1 | 13 | 68.4 | 37 | 78.7 | 3 | 60.0 | 2 | 100.0 | 15 | 83.3 | 25 | 80.6 |
| ≥65 y | ||||||||||||||||
| All-cause CAP (n = 620) | 180 | 29.0 | 160 | 25.8 | 132 | 21.3 | 58 | 9.3 | 79 | 12.7 | 79 | 12.7 | 42 | 6.8 | 60 | 9.7 |
| PCV13 serotypes | 17 | 9.4 | 16 | 10.0 | 17 | 12.9 | 9 | 15.5 | 8 | 10.1 | 4 | 5.1 | 8 | 19.0 | 7 | 11.7 |
| PCV15 serotypes | 19 | 10.6 | 20 | 12.5 | 22 | 16.7 | 13 | 22.4 | 9 | 11.4 | 4 | 5.1 | 8 | 19.0 | 7 | 11.7 |
| PCV20 serotypes | 30 | 16.7 | 33 | 20.6 | 32 | 24.2 | 18 | 31.0 | 10 | 12.7 | 9 | 11.4 | 11 | 26.2 | 13 | 21.7 |
| Most prevalent serotypes (≥1% in total cases) | ||||||||||||||||
| 1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0, | 0 | 0.0 |
| 14 | 1 | 0.6 | 1 | 0.6 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 1.3 | 1 | 2.4 | 0 | 0.0 |
| 19A | 1 | 0.6 | 1 | 0.6 | 0 | 0.0 | 2 | 3.4 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| 3 | 14 | 7.8 | 10 | 6.3 | 14 | 10.6 | 5 | 8.6 | 5 | 6.3 | 1 | 1.3 | 6 | 14.3 | 6 | 10.0 |
| 7F | 1 | 0.6 | 1 | 0.6 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| 8 | 8 | 4.4 | 8 | 5.0 | 8 | 6.1 | 3 | 5.2 | 0 | 0.0 | 2 | 2.5 | 3 | 7.1 | 4 | 6.7 |
| CAP due to S. pneumoniae (n = 206; 33.2%) | 52 | 25.2 | 50 | 24.3 | 42 | 20.4 | 24 | 11.6 | 22 | 10.7 | 19 | 9.2 | 15 | 7.3 | 20 | 9.7 |
| PCV13 serotypes | 17 | 32.7 | 16 | 32.0 | 17 | 40.5 | 9 | 37.5 | 8 | 36.4 | 4 | 21.1 | 8 | 53.3 | 7 | 35.0 |
| PCV15 serotypes | 19 | 36.5 | 20 | 40.0 | 22 | 52.4 | 13 | 54.2 | 9 | 40.9 | 4 | 21.1 | 8 | 53.3 | 7 | 35.0 |
| PCV20 serotypes | 30 | 57.7 | 33 | 66.0 | 32 | 76.2 | 18 | 75.0 | 10 | 45.5 | 9 | 47.4 | 11 | 73.3 | 13 | 65.0 |
Patients might have >1 underlying condition. Six isolates of invasive pneumococcal pneumonias were not serotyped due to lack of sample or lysis.
Abbreviations: CAP, community-acquired pneumonia; COPD, chronic obstructive pulmonary disease; PCV, pneumococcal conjugate vaccine.